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We investigated the association of the levels of ketone bodies
(KBs) with hyperglycemia and with 62 genetic risk variants
regulating glucose levels or type 2 diabetes in the population-
based Metabolic Syndrome in Men (METSIM) study, including
9,398 Finnish men without diabetes or newly diagnosed type 2
diabetes. Increasing fasting and 2-h plasma glucose levels were
associated with elevated levels of acetoacetate (AcAc) and
b-hydroxybutyrate (BHB). AcAc and BHB predicted an increase
in the glucose area under the curve in an oral glucose tolerance
test, and AcAc predicted the conversion to type 2 diabetes in
a 5-year follow-up of the METSIM cohort. Impaired insulin secre-
tion, but not insulin resistance, explained these findings. Of the 62
single nucleotide polymorphisms associated with the risk of type
2 diabetes or hyperglycemia, the glucose-increasing C allele of
GCKR significantly associated with elevated levels of fasting BHB
levels. Adipose tissue mRNA expression levels of genes involved
in ketolysis were significantly associated with insulin sensitivity
(Matsuda index). In conclusion, high levels of KBs predicted sub-
sequent worsening of hyperglycemia, and a common variant of
GCKR was significantly associated with BHB levels. Diabetes
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etone bodies (KBs) serve as an important al-
ternative source of energy in the fasting state.
The circulating levels of KBs in the blood are
determined by the balance of their rates of
production (ketogenesis) and utilization (ketolysis). Keto-
genesis includes the conversion of free fatty acids (FFAs)
into two major KBs, b-hydroxybutyrate (BHB) and aceto-
acetate (AcAc). KBs undergo ketolysis in the extrahepatic
tissues producing energy (1).
Ketogenesis takes place in the liver and is accelerated
by elevated concentrations of FFAs released from the ad-
ipose tissue, which is the major source of KBs (2). Insulin
plays a central role in the regulation of KB levels. Low
levels of insulin increase the rate of ketogenesis, and high
levels of insulin suppress the rate of ketogenesis. Elevated
insulin levels induce KB clearance via increased KB me-
tabolism in extrahepatic tissues (3). Insulin-resistant obese
individuals have a similar sensitivity for insulin-mediated
suppression of ketogenesis as do lean individuals (4). In-
sulin also inhibits ketogenesis by preventing the break-
down of triglycerides into FFAs and glycerol (1,5).
The circulating levels of KBs vary between individuals
with normal and abnormal glucose tolerance. In diabetic
ketoacidosis attributable to low insulin secretion, KB lev-
els are very high, whereas in people with normal glucose
tolerance (NGT), the levels of KBs are usually low (5–7).
Several small studies have found that levels of KBs are
relatively high in patients with type 2 diabetes (6,8), but it
is not known how KBs vary across the entire range of
glucose tolerance. Infusion of KBs into fasting dogs in-
duced hypoglycemia, but when hyperglycemia (9–10
mmol/L) was established by the constant infusion of glu-
cose, AcAc and BHB promoted hyperglycemia (9). Thus,
the effects of KBs on glucose metabolism seem to depend
on the fasting state and on glucose levels. The underlying
mechanisms by which KBs regulate glycemia remain un-
clear. Conflicting evidence has been published on the as-
sociation of KBs with insulin sensitivity as elevated KB
levels have been associated with insulin resistance in some
studies (10–12) and insulin sensitivity in others (13). Sim-
ilarly, KBs have stimulated acute insulin secretion in some
studies (14–17), whereas other studies report increased
KB levels associated with decreased insulin secretion (18–
20). Furthermore, very little is known with regards to the
genetic variants regulating KB metabolism.
The purpose of our study was to investigate 1) the
association of KB levels with fasting and 2-h glucose
levels across the entire range of glucose tolerance, 2) the
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association of KB levels with insulin secretion and insulin
sensitivity, 3) the role of KB levels as predictors of the
worsening of hyperglycemia or type 2 diabetes, 4) the
association of single nucleotide polymorphisms (SNPs)
regulating glucose levels or type 2 diabetes with KB levels,
and 5) the association of adipose tissue mRNA expres-
sion of genes involved in KB metabolism with insulin
sensitivity.
RESEARCH DESIGN AND METHODS
Subjects. The study included 9,398 nondiabetic or newly diagnosed type 2
diabetic men from the population-basedMetabolic Syndrome inMen (METSIM)
study. The study protocol has been previously explained (21). Glucose toler-
ance was classified according to the American Diabetes Association criteria
(22). Among participants, 3,034 (32.3%) had NGT, 4,344 (46.2%) had isolated
impaired fasting glucose (IFG), 312 (3.3%) had isolated impaired glucose tol-
erance (IGT), 1,059 (11.3%) had both IFG and IGT, and 649 (6.9%) had a new
type 2 diabetes. Individuals with previously diagnosed type 1 or type 2 di-
abetes were excluded, and none of the participants were on antidiabetic
medication.
Nondiabetic subjects (n = 4,335) from the original METSIM cohort of 10,197
men have been reexamined (mean follow-up time of 5 years); 4,059 were
nondiabetic and 276 had new type 2 diabetes at follow-up. Characteristics of
the subjects included in the baseline and follow-up studies are given in Sup-
plementary Table 1. The study was approved by the ethics committee of the
University of Eastern Finland and Kuopio University Hospital and was con-
ducted in accordance with the Helsinki Declaration. All study participants
gave written informed consent.
Anthropometric measurements. Height, weight, hip, and waist circumfer-
ence were measured as previously described (21). BMI was calculated as
weight (kg) divided by height (m) squared.
Oral glucose tolerance test. A 2-h oral glucose tolerance test (75 g of glu-
cose) was performed, and samples for plasma glucose and insulin were drawn
at 0, 30, and 120 min.
Laboratory measurements. Plasma glucose was measured by enzymatic
hexokinase photometric assay (Konelab Systems Reagents; Thermo Fischer
Scientific, Vantaa, Finland). Insulin was determined by immunoassay (ADVIA
Centaur Insulin IRI no. 02230141; Siemens Medical Solutions Diagnostics,
Tarrytown, NY). Proton nuclear magnetic resonance (NMR) spectroscopy was
used to measure fasting AcAc and BHB levels (mmol/L) in serum samples (the
mean storage time of 2.5 years). NMR methods have been previously described
in detail (23). The fasting serum samples collected at the baseline study were
stored at 280°C and thawed overnight in a refrigerator prior to sample
preparation. Aliquots of each sample (300 mL) were mixed with 300 mL sodium
phosphate buffer.
Calculations. The trapezoidal method was used to calculate the glucose and
insulin areas under the curve (AUCs) in an oral glucose tolerance test based on
samples collected at 0, 30, and 120 min. Evaluation of insulin sensitivity
(Matsuda ISI) and insulin secretion (InsAUC0–30/GlucAUC0–30) has been pre-
viously described (21,24).
Genotyping.Genotyping of 62 SNPs associated with the risk of type 2 diabetes
or hyperglycemia (25–28) was primarily based on Illumina HumanExome-
12v1_A Beadchip, which includes 247,870 markers focusing on protein-
altering variants selected from .12,000 exome and genome sequences
representing multiple ethnicities and complex traits, as previously described
in detail (29). SNPs that were not available from the exome array were geno-
typed using either the Applied Biosystems TaqMan Allelic Discrimination As-
say (rs10423928, rs231362) or Sequenom iPlex Gold SBE assay (rs12779790,
rs10811661, rs1111875, rs2612067, rs2283228, rs10923931, and rs10010131).
TaqMan genotyping call rate was 100% and discordance rate was 0% among
4.5% DNA samples genotyped in duplicate. Sequenom iPlex call rate was
.96.9% and discordance rate was 0% among 4.2% DNA samples genotyped in
duplicate in METSIM study participants. The concordance rates between
genotyping methods were as follows: Sequenom vs. Taqman 99.3% (based on
.10,000 genotype comparisons), Sequenom vs. ExomeChip 99.5% (based on
.30,000 genotype comparisons), and Taqman vs. ExomeChip 99.3% (based
on .100,000 genotype comparisons). All SNPs were in Hardy-Weinberg
equilibrium at the significance level corrected for multiple testing by the
Bonferroni method (P , 0.0012).
Gene expression analysis. Subcutaneous fat biopsy samples (n = 200) were
obtained from a random sample of the participants of the METSIM baseline
study (age 55.6 6 4.9 years; BMI 26.6 6 3.3 kg/m2). Total RNA was isolated
from these samples using Qiagen miRNeasy Kit according to the manu-
facturer’s instructions. RNA integrity number values were assessed with the
Agilent Bioanalyzer 2100. High-quality samples (RNA integrity number .7.0)
were used for transcriptional profiling with the Illumina Human HT-12 v3 Ex-
pression BeadChip. Genome Studio software (2010.v3) was used to obtain
fluorescent intensities. The HT-12 BeadChip contains 48,804 expression and 786
control probes. Expression data from 19,306 probes were removed because of
1) failure of the probe to align to a genomic or transcriptomic location, 2)
alignment of the probe to multiple genomic or transcriptomic locations, or 3)
presence of SNPs in the probe sequence that may affect hybridization efficiency
as determined by the methodology developed by Barbosa-Morais et al. (30). The
remaining 29,497 probes were processed using nonparametric background
correction, followed by quantile normalization with control and expression
probes using the neqc function in the limma package (R v2.13.0) (31). The 16,223
probes with detection P values ,0.01 in any of the 200 samples were used for
further analysis. Gene expression data have been deposited to Gene Expression
Omnibus (GEO) with the accession number GSE32512.
Statistical analysis. Statistical analyses were conducted using SPSS version
19 (SPSS, Chicago, IL). All traits except age were log-transformed to correct for
their skewed distributions. We used the linear regression model to evaluate
fasting KBs as predictors for glucose AUC at 5-year follow-up. Logistic re-
gression analysis was used to assess the association between KBs and incident
type 2 diabetes. Quintiles of insulin sensitivity and insulin secretion across the
categories of glucose tolerance were compared with the ANOVA (P , 0.0125
was considered as statistically significant given four tests for two KBs and two
glucose tolerance categories). Unstandardized effect sizes (B [SE]) per copy of
the risk alleles of the SNPs investigated were estimated by linear regression
analysis using untransformed dependent variables, and percentage of B from
the mean values of KBs was calculated. After the Bonferroni correction for
multiple testing (for 124 tests given the 62 SNPs and two traits), P , 4.031024
was considered as statistically significant. For both AcAc and BHB, we had
$80% power to detect changes (P , 0.05) in the mean trait values from 0.76 to
4.47% per one copy of the risk allele (risk allele frequencies ranging from 0.05
to 0.5). We correlated adipose tissue mRNA expression of major enzymes
involved in the synthesis and degradation of KBs (KEGG pathway hsa00072)
with insulin sensitivity and insulin secretion (Supplementary Fig. 1). In total,
there were nine enzymes in the pathway, namely, ACAT1, ACAT2, OXCT1,
OXCT2, BDH1, BDH2, HMGCS1, HMGCS2, and HMGCL. Additionally, the
genes encoding the enzymes CPT1A and CPT2 involved in the fatty acid
metabolism (KEGG pathway hsa00071) and ACSS2 gene encoding the enzyme
involved in the activation of acetate to acetyl-coA were included. Among these
genes, expression data were either not available or filtered for ACAT2,
OXCT2, BDH2, and HMGCL.
RESULTS
Levels of KBs across the categories of glucose
tolerance. We evaluated the association of AcAc and
BHB in nondiabetic individuals and individuals with newly
diagnosed type 2 diabetes in the fasting plasma glucose
(FPG) and 2-h plasma glucose (2hPG) categories (Fig. 1).
FPG #5.4 mmol/L and 2hPG #5.9 mmol/L were set as the
reference categories. In the FPG category, AcAc levels
decreased significantly (P , 0.01) in individuals with IFG
by22% (95% CI24 to20) and increased significantly (P,
0.01) in individuals with newly detected diabetes by +64%
(+16 to +109), as compared with the reference category.
BHB level decreased significantly (P , 0.01) in subjects
with IFG by 25% (27 to 23) and increased significantly
(P , 0.01) in the diabetic range by +99% (+6 to +186). In
the 2hPG category, AcAc level increased significantly (P ,
0.01) in subjects with IGT by +21% (+13 to +28) as well as
in newly diagnosed diabetes by +29% (+16 to +42), as
compared with the reference category. BHB level in-
creased nominally in IGT (P , 0.05) by +12% (+4 to +20)
and in newly diagnosed type 2 diabetes (P, 0.01) by +52%
(+23 to +79), as compared with the reference category.
Fasting AcAc and BHB levels correlated significantly with
FPG (r = 20.051, P = 1.9 3 1026, and r = 20.065, P = 1.4 3
1029, respectively) and 2hPG levels (r = 0.079, P = 1.43 10213,
and r = 0.042, P = 9.2 3 1025, respectively).
KBs and the risk of hyperglycemia and incident
diabetes. Follow-up data of 4,335 participants were
available from the ongoing prospective METSIM 5-year
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follow-up study. A total of 276 participants developed in-
cident diabetes between the baseline and follow-up studies
(follow-up of 5 years). Most of the participants who devel-
oped new diabetes on the basis of FPG level (62 of 70
participants) had their FPG in the range of 7.0–7.5 mmol/L,
and most of the participants who developed new diabetes
on the basis of 2hPG had their 2hPG level (52 of 80 partic-
ipants) in the range of 11.1–12.0 mmol/L. AcAc and BHB
levels adjusted for confounding factors known to increase
the risk of diabetes (age, BMI, smoking, and physical activity)
predicted an increase in glucose AUC evaluated as a con-
tinuous variable at follow-up (P = 2.3 3 1024 and P = 5.7 3
1026, respectively), and quite similar results were obtained
for the comparison of the highest quartile of glucose AUC
versus the three lowest quartiles of glucose AUC (P = 7.93
1028 and P = 3.4 3 1026, respectively) (Table 1). After fur-
ther adjustment for baseline glucose AUC, the associations
lost their statistical significance. The highest quartile of AcAc
adjusted for age, BMI, smoking, and physical activity pre-
dicted conversion to type 2 diabetes (odds ratio [OR] 1.32
[95% CI 1.00–1.74], P = 0.047) (Table 2), and also after fur-
ther adjustment for FPG (OR 1.41 [1.06–1.89], P = 0.019).
Adjustment for 2hPG, instead of FPG, abolished statistical
significance (P = 0.423). When analyzed in glucose tolerance
categories, AcAc predicted incident diabetes in individuals
with IFG (OR 1.49 [1.12–1.99], P = 0.007) after the adjustment
for confounding factors.
Additional adjustment for insulin sensitivity strength-
ened the association of KBs with development of hyper-
glycemia and conversion to type 2 diabetes, whereas
insulin secretion weakened/abolished these associations
(Supplementary Table 2).
Levels of KBs across the quintiles of insulin sensi-
tivity and insulin secretion. To study the mechanisms
by which KBs could be linked to hyperglycemia, we in-
vestigated their association with insulin sensitivity and
insulin secretion in nondiabetic individuals. The levels of
AcAc and BHB increased significantly (P , 0.01) in the
highest quintile of Matsuda ISI up to 29 and 41%, re-
spectively (Fig. 2). AcAc and BHB levels decreased sig-
nificantly (P , 0.01) by 223 and 229%, respectively, in the
highest quintile of insulin secretion (adjusted for insulin
sensitivity) compared with the lowest quintile. In a multi-
variate linear regression model including insulin sensitivity
and insulin secretion as independent variables, insulin
sensitivity remained inversely associated with AcAc (P ,
1.0 3 10219) and BHB levels (P , 1.0 3 10222).
FIG. 1. Mean values and their 95% CIs of fasting levels of AcAc (A and B) and BHB (C andD) across the fasting and 2-h glucose categories. P values
(from ANOVA post hoc tests) indicate statistical significance with respect to the reference category (FPG £5.4 mmol/L and 2hPG £5.9 mmol/L).
*P < 0.05; **P < 0.01. OGTT, oral glucose tolerance test.
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Association of risk SNPs for type 2 diabetes or hy-
perglycemia with the levels of KBs. Associations of 62
risk SNPs for type 2 diabetes or hyperglycemia with KB
levels are shown in Table 3. After correction for multiple
testing (threshold of statistical significance, P, 4.03 1024),
the glucose-increasing C allele of rs780094 of GCKR showed
a significant association with elevated levels of BHB (effect
size +5.6% per the C allele, P = 3.7 3 1026 after adjusting for
age and BMI) and a nominally significant association with
AcAc (+3.9%, P = 0.003). Additionally, there were nominally
significant associations for SNPs of FADS1, ANK1, GIPR,
HMGA2, and SLC2A2 with the levels of AcAc or BHB or
both (Table 3).
Gene expression of genes involved in KB metabolism.
Correlations of adipose tissue mRNA expression with the
most important genes regulating FFA oxidation, ketogen-
esis, and ketolysis are shown in Table 4. Pearson corre-
lation of fasting FFAs with AcAc was 0.483 (P, 0.001) and
with BHB was 0.443 (P , 0.001) in nondiabetic METSIM
participants, and therefore genes regulating FFA metabo-
lism were included in statistical analyses. Adipose tissue
mRNA expression of the gene encoding CPT1A (carnitine
palmitoyltransferase 1A) was positively correlated with
glucose AUC and inversely with Matsuda ISI. This enzyme
regulates the binding of carnitine to long-chain fatty acids,
allowing them to be transported to the mitochondria for
FFA oxidation. Expression of genes regulating ketogen-
esis, HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase
1, soluble) and HMGCS2 (3-hydroxy-3-methylglutaryl-CoA
synthase 2, mitochondrial), did not correlate significantly
with glucose AUC, insulin sensitivity, or insulin secretion.
In contrast, significant correlations were found with adi-
pose tissue mRNA expression levels of several genes asso-
ciated with ketolysis with glucose metabolism parameters.
Of these genes, ACAT1 expression had the most significant
correlations with glucose AUC (r =20.314, P = 6.13 1026),
Matsuda ISI (r = 0.479, P = 7.1 3 10213), and insulin se-
cretion (r = 20.444, P = 7.0 3 10211). ACAT1 encodes
acetyl-CoA acetyltransferase 1, an enzyme responsible for
the last step in KB breakdown where two molecules of
acetyl-CoA are generated from acetoacetyl-CoA (Supple-
mentary Fig. 1). Similarly, expression of other genes reg-
ulating ketolysis, BDH1 (BHB dehydrogenase, type 1),
OXCT1 (3-oxoacid CoA transferase 1), and ACSS2 (acyl-
CoA synthetase short-chain family member 2), was in-
versely correlated with glucose AUC and insulin secretion
and positively correlated with Matsuda ISI. Adipose tissue
mRNA expression of ketolysis genes did not correlate with
the levels of KBs (all correlations ,0.10, P = NS).
DISCUSSION
In this population-based cross-sectional study of 9,398 men
with prospective 5-year follow-up data on 4,335 men, we
evaluated the relationship between the levels of KBs and
hyperglycemia, the levels of KBs as risk markers for in-
cident type 2 diabetes, and the mechanisms explaining
these associations. Our study reports several novel find-
ings: 1) KB levels increased in participants with IGT and
type 2 diabetes at baseline, 2) KBs predicted the worsen-
ing of hyperglycemia and incident type 2 diabetes in a
5-year follow-up, 3) the association of KBs with the wors-
ening of hyperglycemia was attributable to impaired in-
sulin secretion, and not to insulin resistance, 4) of the 62
risk variants for type 2 diabetes or hyperglycemia, the
glucose-increasing major C allele of rs780094 of GCKR
was associated significantly with elevated BHB levels, and
5) adipocyte RNA expression of several key enzymes in-
volved in ketolysis correlated inversely with glycemia and
insulin secretion and positively with insulin sensitivity.
KBs and hyperglycemia. High levels of KBs have been
observed in individuals with diabetes (6,8,32), but there is
no previous information about KB levels in the nondiabetic
glucose range. In our study, the levels of AcAc and BHB
were slightly decreased in subjects with IFG, but increased
in the diabetic range (FPG $9.0 mmol/L) up to 64 and 99%,
respectively. In contrast, in the 2-h glucose categories, the
levels of AcAc and BHB were already somewhat increased
in subjects with NGT and IGT, and significantly increased
up to 29 and 52%, respectively, in individuals with newly
diagnosed diabetes (2hPG $13 mmol/L). Thus, our study
provides clear evidence that high levels of KBs are not
only indicators of diabetic hyperglycemia but also markers
of disturbed glucose metabolism in the prediabetic state.
We also observed that the levels of AcAc and BHB
predicted an increase in glucose AUC in nondiabetic in-
dividuals, but the associations were abolished after the
TABLE 1
Association of baseline levels of fasting AcAc and BHB as predictors of glucose AUC at 5-year follow-up
Glucose AUC at follow-up as a continuous
variable Glucose AUC at follow-up as Q4 vs. Q1–Q3
n B SE P n OR 95% CI P
AcAc (mmol/L) 4,181 39.5 10.1 2.3 3 1024 4,181 1.56 1.33–1.84 7.9 3 1028
BHB (mmol/L) 4,179 51.6 11.1 5.7 3 1026 4,200 1.46 1.25–1.72 3.4 3 1026
Statistical analyses were performed with the glucose AUC as a continuous variable and as the highest quartile (Q4) vs. the three lowest
quartiles (Q1–Q3) combined. B and SE were obtained from multiple linear regression. ORs and their 95% CIs were obtained from logistic
regression analyses. P values are adjusted for age, BMI, smoking, and physical activity. Bold type indicates statistical significance.
TABLE 2
Association of baseline levels of fasting AcAc and BHB (highest
quartile vs. the three lowest quartiles) with incident type 2
diabetes during 5-year follow-up
OR 95% CI P OR 95% CI P*
AcAc (mmol/L) 1.37 (1.05–1.80) 0.022 1.32 (1.00–1.74) 0.047
BHB (mmol/L) 1.00 (0.76–1.32) 0.996 1.03 (0.77–1.36) 0.864
ORs and their 95% CIs were obtained from multiple logistic regres-
sion analyses. The number of individuals with incident type 2 diabe-
tes at follow-up was 269 (40% developed diabetes based on FPG, 46%
based on 2hPG, and 14% based on both FPG and 2hPG levels), and
the number of individuals who remained nondiabetic was 4,008. P is
unadjusted. *P adjusted for age, BMI, smoking, and physical activity.
Bold type indicates statistical significance.
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adjustment for glucose AUC at baseline. This could in-
dicate an important link between the levels of KBs and
glucose metabolism, but on the other hand, the clinical
importance of KBs as markers for the worsening of hy-
perglycemia might be limited. AcAc, but not BHB, pre-
dicted the development of new type 2 diabetes during
a prospective 5-year follow-up of the METSIM cohort, in-
dependent of known risk factors for type 2 diabetes and
fasting glucose level at baseline. The reasons why KBs
predicted very significantly the worsening of glycemia, but
not so clearly incident diabetes, are FPG and 2hPG levels
at the diagnosis of type 2 diabetes, which were often only
marginally elevated (FPG in the range of 7.0–7.5 mmol/L
and 2hPG in the range of 11.1–12.0 mmol/L), whereas the
levels of KBs were significantly increased at higher glucose
levels (FPG levels exceeding 8.0 mmol/L and 2hPG levels
exceeding 12.0 mmol/L) (Fig. 1). Our results suggest that
fasting AcAc could be a new marker for the development
of incident diabetes. It is of interest to note that a recent
study identified a-hydroxybutyrate, an organic acid de-
rived from a-ketobutyrate, as a biomarker of insulin sen-
sitivity in subjects with NGT (33).
To study the mechanisms by which KBs can increase the
risk of hyperglycemia, we investigated the association of
KB levels with insulin sensitivity and insulin secretion.
Surprisingly, we found that high levels of KBs were asso-
ciated with high insulin sensitivity in the nondiabetic glu-
cose range at baseline, similar to recent findings in young
Finnish adults (13). Furthermore, insulin sensitivity was
significantly correlated with the key enzymes of ketolysis
(Table 4), which suggests that in insulin-sensitive individ-
uals, KBs are rapidly converted to acetyl-CoA, which
stimulates oxidative phosphorylation and mitochondrial
generation of ATP. Based on these findings, it is not likely
that insulin resistance is an important mechanism in the
prediction of hyperglycemia by elevated KB levels. This
FIG. 2. Mean values and their 95% CIs of fasting levels of AcAc and BHB across the quintiles of Matsuda ISI (A and C) and Matsuda ISI–
adjusted InsAUC0–30/GlucAUC0–30 (B and D) in nondiabetic subjects. P values (from ANOVA post hoc tests) indicate statistical significance
with respect to the reference category (first lowest quintiles). *P < 0.05; **P < 0.01. Quintiles of Matsuda ISI (A and C): first (lowest)
(£3.130), second (3.131–4.857), third (4.858–6.808), fourth (6.809–9.621), and fifth (highest) (‡9.622). Quintiles of Matsuda ISI–adjusted
InsAUC0–30/GlucAUC0–30 (B and D): first (lowest) (£22.439), second (22.440–30.243), third (30.244–35.655), fourth (35.656–40.445), and
fifth (highest) (‡40.446).
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TABLE 3







%B P P* %B P P*
rs552976 ABCB11/G6PC2 8,120 G/A 66.0 20.4 0.562 0.555 20.1 0.825 0.871
rs4607103 ADAMTS9 8,120 C/T 74.1 23.7 0.007 0.009 23.3 0.067 0.079
rs11708067 ADCY5 8,117 A/G 84.1 21.0 0.462 0.532 20.5 0.949 0.945
rs10885122 ADRA2A 8,120 G/T 84.3 20.5 0.639 0.681 21.1 0.989 0.946
rs516946 ANK1 8,120 C/T 80.5 +3.4 0.042 0.036 +3.4 0.014 0.011
rs4737009 ANK1 8,120 G/A 20.9 +0.6 0.481 0.494 +1.7 0.080 0.097
rs459193 ANKRD55 8,120 G/A 67.0 20.3 0.624 0.666 20.1 0.618 0.653
rs7202877 BCAR1 8,120 T/G 85.5 0.7 0.464 0.475 0.6 0.743 0.809
rs243021 BCL11A 8,120 G/A 43.6 21.3 0.174 0.153 20.9 0.232 0.188
rs12779790 CDC123 8,007 A/G 21.1 0.7 0.988 0.951 0.1 0.694 0.593
rs7754840 CDKAL1 8,120 G/C 36.9 21.0 0.555 0.471 20.2 0.651 0.483
rs10811661 CDKN2B 8,488 T/C 85.3 0.3 0.313 0.327 1.1 0.303 0.289
rs1552224 CENTD2 8,119 A/C 74.7 1.9 0.022 0.025 1.8 0.099 0.133
rs13292136 CHCHD9 8,056 C/T 86.6 0.8 0.397 0.406 0.2 0.843 0.870
rs11605924 CRY2 8,108 A/C 52.9 1.7 0.124 0.097 3.4 0.002 0.001
rs2191349 DGKB 8,120 G/T 42.8 1.3 0.152 0.160 2.3 0.038 0.047
rs174550 FADS1 8,119 T/C 57.7 23.2 6.7 3 1024 5.5 3 1024 23.1 0.151 0.112
rs11071657 FAM148B/C2CD4B 8,118 A/G 69.1 20.1 0.446 0.505 22.7 0.032 0.019
rs1046896 FN3K 8,120 C/T 25.0 1.1 0.450 0.436 1.1 0.745 0.709
rs9939609 FTO 8,100 T/A 40.1 20.4 0.961 0.839 21.2 0.340 0.581
rs560887 G6PC2 8,120 C/T 72.1 20.6 0.333 0.329 20.3 0.987 0.908
rs4607517 GCK 8,120 G/A 10.1 21.0 0.757 0.684 20.9 0.506 0.423
rs1799884 GCK 8,120 C/T 12.1 1.0 0.757 0.684 0.9 0.506 0.423
rs780094 GCKR 8,120 C/T 62.2 3.9 0.005 0.003 5.6 8.3 3 1026 3.7 3 1026
rs10423928 GIPR 8,302 T/A 21.6 23.8 0.001 0.001 23.7 0.004 0.003
rs7034200 GLIS3 8,103 C/A 48.8 1.5 0.422 0.406 0.1 0.798 0.759
rs13389219 GRB14 8,120 C/T 67.0 0.5 0.817 0.759 0.1 0.805 0.641
rs1408272 HFE 8,120 T/G 5.00 2.0 0.160 0.180 0.3 0.770 0.879
rs1111875 HHEX 8,361 C/T 53.6 0.4 0.447 0.414 0.6 0.225 0.228
rs7177055 HMG20A 8,120 A/G 66.0 0.1 0.668 0.557 0.3 0.395 0.247
rs2612067 HMGA2 8,353 T/G 6.90 25.9 0.005 0.006 26.0 0.009 0.010
rs7957197 HNF1A 8,120 T/A 78.5 0.3 0.700 0.589 0.5 0.648 0.786
rs7501939 HNF1B 8,119 C/T 27.4 20.8 0.619 0.630 22.2 0.397 0.405
rs4402960 IGF2BP2 8,119 G/T 32.0 20.7 0.379 0.414 0.4 0.793 0.765
rs7578326 IRS1 8,119 A/G 64.6 1 0.340 0.363 0.7 0.315 0.412
rs864745 JAZF1 8,117 T/C 51.6 21.7 0.117 0.131 21.5 0.341 0.374
rs5219 KCNJ11 8,119 C/T 47.1 20.9 0.730 0.669 21.3 0.115 0.086
rs2283228 KCNQ1 8,631 A/C 94.0 2.2 0.362 0.314 0.9 0.941 0.863
rs231362 KCNQ1 8,388 G/A 51.9 21.8 0.050 0.041 21.7 0.261 0.199
rs972283 KLF14 8,120 G/A 57.5 22.8 0.055 0.066 22.7 0.009 0.014
rs10842994 KLHDC5 8,120 C/T 84.6 1.2 0.794 0.718 0.6 0.941 0.803
rs7944584 MADD 8,120 A/T 81.9 1.2 0.154 0.143 0.9 0.518 0.460
rs12970134 MC4R 8,120 G/A 17.5 23.6 0.006 0.005 22.0 0.129 0.100
rs10830963 MTNR1B 8,119 C/G 36.1 0.8 0.475 0.477 0.8 0.707 0.786
rs1387153 MTNR1B 8,120 C/T 39.4 20.5 0.657 0.682 20.2 0.542 0.499
rs10923931 NOTCH2 8,631 G/T 14.0 20.2 0.701 0.694 21.1 0.868 0.869
rs1801282 PPARG 8,119 C/G 84.9 3.0 0.036 0.037 20.03 0.996 0.918
rs8042680 PRC1 8,119 C/A 32.9 2.0 0.137 0.126 2.4 0.282 0.319
rs340874 PROX1 8,120 T/C 39.7 20.6 0.905 0.868 20.1 0.760 0.843
rs11920090 SLC2A2 8,120 T/A 86.7 23.8 0.011 0.011 24.9 0.018 0.017
rs13266634 SLC30A8 8,119 C/T 60.4 20.6 0.300 0.308 20.1 0.576 0.532
rs10401969 SUGP1 8,120 C/T 94.0 20.5 0.943 0.964 +2.3 0.507 0.462
rs7903146 TCF7L2 8,120 C/T 17.8 0.7 0.811 0.805 0.3 0.850 0.956
rs7578597 THADA 8,120 T/C 95.1 21.0 0.228 0.218 0.2 0.429 0.409
rs2796441 TLE1 8,120 G/A 59.1 20.3 0.999 0.861 21.4 0.401 0.272
rs896854 TP53INP1 8,120 C/T 45.9 0.8 0.963 0.903 1.2 0.269 0.421
rs7961581 TSPAN8 8,041 T/C 19.7 20.4 0.779 0.712 21.8 0.634 0.669
rs17271305 VPS13C 8,120 G/A 50.5 0.4 0.900 0.853 1.0 0.272 0.226
rs10010131 WFS1 8,631 G/A 55.5 20.4 0.491 0.506 20.3 0.745 0.758
rs4457053 ZBED3 8,120 A/G 21.4 21.6 0.403 0.417 0.5 0.632 0.617
Continued on next page
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was clearly demonstrated by our 5-year follow-up data that
showed that adjustment for Matsuda ISI did not weaken
the association of KBs with the development of hypergly-
cemia. In contrast, impaired insulin secretion substantially
weakened or abolished the association of KBs with the
development of hyperglycemia and the conversion to type
2 diabetes. These findings emphasize the crucial role of
impaired insulin secretion as a regulator of hyperglycemic
effects of KBs. Adequate insulin secretion relative to in-
sulin sensitivity maintains low levels of KBs by suppress-
ing the expression of hormone-sensitive lipase and thus
prevents the release of FFAs from adipose tissue, which is
the major source of hepatic ketogenesis and high circu-
lating levels of KBs (5,19,34).
Risk SNPs for hyperglycemia or type 2 diabetes and
their association with the levels of KBs. The associa-
tion of KB levels with hyperglycemia prompted us to in-
vestigate the role of risk SNPs for type 2 diabetes and
hyperglycemia in KB metabolism. Of the 62 SNPs analyzed,
only the glucose-increasing major C allele of rs780094 of
GCKR (encoding glucokinase regulatory protein) was
significantly associated with increased BHB levels and
nominally associated with AcAc levels. Glucokinase is the
principal component in sensing the glucose level and plays
a vital role in whole-body glucose homeostasis, and its
activity is regulated by GCKR in the liver (35). The C allele
of rs780094 of GCKR has been previously reported to be
associated with fasting glycemia, type 2 diabetes, insulin
resistance, decreased levels of total and VLDL triglyc-
erides, decreased levels of alanine and isoleucine, and
elevated levels of glutamine (36–40). The association of
rs780094 with KB levels adds further to the pleiotropy of
the multiple effects of GCKR.
There were several nominally significant associations of
different SNPs of ANK1, GIPR, HMGA2, SLC2A2, and
FADS1 with KB levels. However, these associations did
not have a consistent pattern (increase/decrease or asso-
ciations with AcAc or BHB or both), and therefore these
results need to be replicated in other population-based
studies before making conclusions on the implications of
these findings.
Limitations. Our study included only middle-aged Finnish
men, and the applicability of these results to women or to
other ethnic and racial groups remains unknown. Although
our cohort included.9,000 men, the power of our study to
demonstrate significant associations of KBs with SNPs
regulating glucose levels or the risk of type 2 diabetes is
limited.
In conclusion, our large population-based study of 9,398
men shows that elevated levels of KBs associate with
fasting and 2-h glucose and predict the worsening of
glycemia and incident type 2 diabetes. Impaired insulin
secretion, but not insulin resistance, explained these
findings. The major C allele of rs780094 of GCKR, which is










%B P P* %B P P*
rs11634397 ZFAND6 8,120 G/A 59.1 20.8 0.777 0.777 21.5 0.296 0.290
rs12571751 ZMIZ1 8,120 A/G 55.5 20.6 0.531 0.579 20.6 0.348 0.391
Major/minor (maj/min) alleles of each SNP are shown. Risk alleles for hyperglycemia or type 2 diabetes are underlined. Effect sizes (indicated
as % of B from the mean) per risk allele were calculated in nondiabetic participants (n = 8,007–8,631) using untransformed variable. P values
were obtained from linear regression analysis using transformed variables. Significant P values (P , 4.0 3 1024) after the Bonferroni
adjustment for multiple testing (for 124 tests given 62 SNPs and two traits) are given in bold and underlined. Significant P values are given
in bold. P is unadjusted. *P is adjusted for age and BMI.
TABLE 4
Pearson correlations of adipose tissue mRNA expression of major enzymes involved in fatty acid oxidation, ketogenesis, and ketolysis
with glucose AUC, Matsuda ISI, and Matsuda ISI–adjusted InsAUC0–30/GlucAUC0–30
Glucose AUC Matsuda ISI InsAUC0–30/ GlucAUC0–30
r P r P r P
Function/gene
Fatty acid oxidation
CPT1A 0.198 4.9 3 1023 20.229 1.1 3 1023 0.168 0.019
CPT2 20.068 0.340 0.249 3.7 3 1024 20.274 1.0 3 1024
Ketogenesis
HMGCS2 0.078 0.273 20.013 0.851 0.006 0.936
HMGCS1 20.042 0.557 0.088 0.217 20.068 0.342
Ketolysis
BDH1 20.222 1.6 3 1023 0.425 3.4 3 10210 20.408 3.0 3 1029
OXCT1 20.121 0.088 0.232 9.4 3 1024 20.182 0.011
ACAT1 20.314 6.1 3 1026 0.479 7.1 3 10213 20.444 7.0 3 10211
ACSS2 20.108 0.130 0.307 9.7 3 1026 20.274 1.0 3 1024
CPT1A, carnitine palmitoyltransferase 1A; CPT2, carnitine palmitoyltransferase II; HMGCS2, 3-hydroxy-3-methylglutaryl-CoA synthase 2
(mitochondrial); HMGCS1, 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble); BDH1, 3-hydroxybutyrate dehydrogenase, type 1; OXCT1,
3-oxoacid CoA transferase 1; ACAT1, acetyl-CoA acetyltransferase 1; ACSS2, acyl-CoA synthetase short-chain family member 2.
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